Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
Go back to Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting| (NASDAQ: STRO) | Delayed: 16.09 -0.26 (1.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.35 | 52 Week High | $ | |||
| Open | $16.43 | 52 Week Low | $ | |||
| Day High | $16.55 | P/E | N/A | |||
| Day Low | $16.00 | EPS | $ | |||
| Volume | 23,149 | |||||
